Omnicell, Inc. (OMCL) Expected to Announce Quarterly Sales of $173.85 Million
Analysts predict that Omnicell, Inc. (NASDAQ:OMCL) will announce sales of $173.85 million for the current quarter, according to Zacks. Three analysts have made estimates for Omnicell’s earnings. The lowest sales estimate is $172.60 million and the highest is $175.37 million. Omnicell posted sales of $172.91 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 0.5%. The firm is expected to issue its next quarterly earnings results after the market closes on Thursday, July 27th.
According to Zacks, analysts expect that Omnicell will report full-year sales of $173.85 million for the current financial year, with estimates ranging from $726.75 million to $740.30 million. For the next financial year, analysts anticipate that the company will post sales of $817.51 million per share, with estimates ranging from $806.72 million to $827.26 million. Zacks’ sales averages are an average based on a survey of research firms that cover Omnicell.
Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, May 4th. The company reported $0.06 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.36. The firm had revenue of $150.90 million during the quarter, compared to analyst estimates of $152.63 million. Omnicell had a negative net margin of 1.45% and a positive return on equity of 2.66%. The company’s revenue for the quarter was down 12.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.35 EPS.
A number of brokerages have recently issued reports on OMCL. Cantor Fitzgerald reaffirmed a “buy” rating and set a $47.00 price target on shares of Omnicell in a report on Tuesday. Zacks Investment Research raised shares of Omnicell from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. BidaskClub raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 10th. Piper Jaffray Companies downgraded shares of Omnicell from an “overweight” rating to a “neutral” rating and set a $40.00 price target on the stock. in a report on Friday, April 21st. Finally, Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $53.00 price target (up previously from $43.00) on shares of Omnicell in a report on Tuesday, April 25th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $47.00.
In other Omnicell news, Chairman Randall A. Lipps sold 9,900 shares of Omnicell stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $43.00, for a total transaction of $425,700.00. Following the transaction, the chairman now owns 208,982 shares of the company’s stock, valued at $8,986,226. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP J Christopher Drew sold 10,625 shares of Omnicell stock in a transaction that occurred on Tuesday, May 9th. The shares were sold at an average price of $40.97, for a total transaction of $435,306.25. Following the transaction, the vice president now directly owns 152,057 shares in the company, valued at approximately $6,229,775.29. The disclosure for this sale can be found here. In the last three months, insiders sold 82,800 shares of company stock worth $3,474,801. 3.77% of the stock is currently owned by insiders.
A number of institutional investors have recently modified their holdings of the stock. SFE Investment Counsel purchased a new position in shares of Omnicell during the first quarter valued at $332,000. Legato Capital Management LLC increased its position in shares of Omnicell by 3,965.0% in the first quarter. Legato Capital Management LLC now owns 42,154 shares of the company’s stock valued at $1,037,000 after buying an additional 41,117 shares in the last quarter. Louisiana State Employees Retirement System increased its position in shares of Omnicell by 2.7% in the first quarter. Louisiana State Employees Retirement System now owns 15,100 shares of the company’s stock valued at $614,000 after buying an additional 400 shares in the last quarter. Juncture Wealth Strategies LLC increased its position in shares of Omnicell by 7.2% in the first quarter. Juncture Wealth Strategies LLC now owns 29,692 shares of the company’s stock valued at $1,207,000 after buying an additional 1,998 shares in the last quarter. Finally, First National Bank of Omaha purchased a new position in shares of Omnicell during the first quarter valued at $865,000. 96.35% of the stock is currently owned by institutional investors and hedge funds.
Shares of Omnicell (NASDAQ:OMCL) traded down 0.80% during trading on Wednesday, reaching $43.45. 76,515 shares of the company were exchanged. The stock’s 50-day moving average is $43.04 and its 200-day moving average is $39.75. The firm’s market cap is $1.61 billion. Omnicell has a 52-week low of $30.35 and a 52-week high of $44.60.
COPYRIGHT VIOLATION NOTICE: “Omnicell, Inc. (OMCL) Expected to Announce Quarterly Sales of $173.85 Million” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/07/26/omnicell-inc-omcl-expected-to-announce-quarterly-sales-of-173-85-million.html.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.